JP2006069958A - Age resistor - Google Patents
Age resistor Download PDFInfo
- Publication number
- JP2006069958A JP2006069958A JP2004255288A JP2004255288A JP2006069958A JP 2006069958 A JP2006069958 A JP 2006069958A JP 2004255288 A JP2004255288 A JP 2004255288A JP 2004255288 A JP2004255288 A JP 2004255288A JP 2006069958 A JP2006069958 A JP 2006069958A
- Authority
- JP
- Japan
- Prior art keywords
- quinone
- aging agent
- acid
- quinone derivative
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004059 quinone derivatives Chemical class 0.000 claims abstract description 21
- 235000001014 amino acid Nutrition 0.000 claims abstract description 17
- 150000001413 amino acids Chemical class 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims abstract description 4
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims abstract description 3
- 239000004475 Arginine Substances 0.000 claims abstract description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims abstract description 3
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims abstract description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims abstract description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims abstract description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000003704 aspartic acid Nutrition 0.000 claims abstract description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000013922 glutamic acid Nutrition 0.000 claims abstract description 3
- 239000004220 glutamic acid Substances 0.000 claims abstract description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 230000003712 anti-aging effect Effects 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 12
- 235000013373 food additive Nutrition 0.000 claims description 5
- 239000002778 food additive Substances 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 4
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
- 235000009697 arginine Nutrition 0.000 claims description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 2
- 235000018417 cysteine Nutrition 0.000 claims description 2
- 235000004554 glutamine Nutrition 0.000 claims description 2
- 235000013930 proline Nutrition 0.000 claims description 2
- 150000004053 quinones Chemical class 0.000 claims description 2
- 235000004400 serine Nutrition 0.000 claims description 2
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 abstract description 12
- 206010012289 Dementia Diseases 0.000 abstract description 6
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 229960003067 cystine Drugs 0.000 abstract 1
- 229940024606 amino acid Drugs 0.000 description 13
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 239000001530 fumaric acid Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- 239000004278 EU approved seasoning Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 229960005261 aspartic acid Drugs 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000011194 food seasoning agent Nutrition 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- GUBYYJQSWUYTDA-UHFFFAOYSA-N 12-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-2,6,10-trimethyldodeca-2,6,10-trienoic acid Chemical compound COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)C(O)=O)=C(C)C1=O GUBYYJQSWUYTDA-UHFFFAOYSA-N 0.000 description 1
- FFYGDROIZZHGKC-UHFFFAOYSA-N 12-(5-hydroxy-2,3,4-trimethoxy-6-methylphenyl)-2,6,10-trimethyldodeca-2,6,10-trienoic acid Chemical compound C(=O)(O)C(=CCCC(=CCCC(=CCC=1C(=C(C(=C(C1C)O)OC)OC)OC)C)C)C FFYGDROIZZHGKC-UHFFFAOYSA-N 0.000 description 1
- KAAGASOFSKQNCN-UHFFFAOYSA-N 16-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-2,6,10,14-tetramethylhexadeca-2,6,10,14-tetraenoic acid Chemical compound COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C(O)=O)=C(C)C1=O KAAGASOFSKQNCN-UHFFFAOYSA-N 0.000 description 1
- RRYHHMIOEWOPMI-UHFFFAOYSA-N 16-(5-hydroxy-2,3,4-trimethoxy-6-methylphenyl)-2,6,10,14-tetramethylhexadeca-2,6,10,14-tetraenoic acid Chemical compound C(=O)(O)C(=CCCC(=CCCC(=CCCC(=CCC=1C(=C(C(=C(C1C)O)OC)OC)OC)C)C)C)C RRYHHMIOEWOPMI-UHFFFAOYSA-N 0.000 description 1
- XVANLHMHRRIBGY-UHFFFAOYSA-N 8-(4,5-dimethoxy-2-methyl-3,6-dioxocyclohexa-1,4-dien-1-yl)-2,6-dimethylocta-2,6-dienoic acid Chemical compound COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)C(O)=O)=C(C)C1=O XVANLHMHRRIBGY-UHFFFAOYSA-N 0.000 description 1
- GQIWCKUHDJIDDQ-UHFFFAOYSA-N 8-(5-hydroxy-2,3,4-trimethoxy-6-methylphenyl)-2,6-dimethylocta-2,6-dienoic acid Chemical compound COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)C(O)=O)C(OC)=C1OC GQIWCKUHDJIDDQ-UHFFFAOYSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- KOFCQMJJSRZXIJ-UHFFFAOYSA-N Cc(c(O)c1OC)c(C)c(OC)c1OC Chemical compound Cc(c(O)c1OC)c(C)c(OC)c1OC KOFCQMJJSRZXIJ-UHFFFAOYSA-N 0.000 description 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000013677 cerebrovascular dementia Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000015071 dressings Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- UIXPTCZPFCVOQF-UHFFFAOYSA-N ubiquinone-0 Chemical compound COC1=C(OC)C(=O)C(C)=CC1=O UIXPTCZPFCVOQF-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
Description
本発明は、慢性の組織呼吸不全による細胞死と、それに伴う老化症状を防止する老化防止剤、及びそれを用いた液体飲料、食品添加剤に関する。 The present invention relates to an anti-aging agent for preventing cell death due to chronic tissue respiratory failure and aging symptoms associated therewith, a liquid beverage using the same, and a food additive.
本発明者らは、先にアミノ酸がヒト培養細胞の低酸素環境における細胞死を防止し（非特許文献１）、同時に、細胞内のCoQが増量することから、細胞は酸素利用が困難な状態においては酸素を利用せずにエネルギーを得る、Prop−CoA代謝系を賦活させて生存する方法を見出すものと想定した。 The present inventors have previously described that amino acids prevent cell death in a hypoxic environment of cultured human cells (Non-Patent Document 1), and at the same time, the amount of CoQ in the cells increases, so that the cells are in a state where oxygen utilization is difficult In, we assumed that we will find a method of obtaining energy without using oxygen and activating the Prop-CoA metabolic system to survive.
またCoQ１０は、加齢と共に生合成機能が低下し、各組織における含量が低下するため、CoQ１０の投与により、心筋梗塞、再灌流における心筋保護、心筋症患者の心駆駆出率及び生存率の増加、免疫機能の増強、抗酸化作用、血圧低下、疲労回復、寿命の延長、動脈硬化の予防等が報告されている（非特許文献２）。
本発明は、痴呆症等の老化症状を改善する老化防止剤、それを用いた液体飲料、食品添加剤を提供することを課題とする。 An object of the present invention is to provide an anti-aging agent that improves aging symptoms such as dementia, a liquid beverage using the same, and a food additive.
本発明は、課題の解決手段として、アミノ酸及びこれらの薬理学的に許容できる塩、並びにキノン誘導体若しくはキノンを含有する老化防止剤、及びそれを用いた液体飲料、食品添加剤を提供するものである。 The present invention provides an amino acid and a pharmacologically acceptable salt thereof, an anti-aging agent containing a quinone derivative or a quinone, a liquid beverage using the same, and a food additive as a means for solving the problems. is there.
本発明の老化防止剤は、組織呼吸障害に起因する脳血管型及びアルツハイマー型痴呆の改善効果、老化に伴う心不全、高血圧、動脈硬化等の症状を改善する効果を有している。 The anti-aging agent of the present invention has an effect of improving cerebrovascular and Alzheimer-type dementia caused by tissue respiratory disorder, and an effect of improving symptoms such as heart failure associated with aging, hypertension, and arteriosclerosis.
本発明の老化防止剤に含まれるアミノ酸は、アスパラギン酸、アルギニン、グルタミン、グルタミン酸、プロリン、セリン、システィン及びこれらの薬理学的に許容できる塩から選ばれる１種又は２種以上のものが好ましい。薬理学的に許容できる塩としては、塩酸、硫酸等の無機酸の塩、酢酸、フマル酸等の有機酸の塩、ナトリウム、カリウム等のアルカリ金属の塩等を挙げることができる。 The amino acid contained in the antiaging agent of the present invention is preferably one or more amino acids selected from aspartic acid, arginine, glutamine, glutamic acid, proline, serine, cysteine and pharmacologically acceptable salts thereof. Examples of pharmacologically acceptable salts include salts of inorganic acids such as hydrochloric acid and sulfuric acid, salts of organic acids such as acetic acid and fumaric acid, and salts of alkali metals such as sodium and potassium.
２種以上のアミノ酸を組み合わせて用いるときは、投与された組織細胞ミトコンドリア内のフマール酸、コハク酸濃度が高まるように代謝上の配慮をするとともに、アミノ酸が溶解した溶液の液性が中性になるようにすることが好ましく、塩基性アミノ酸、中性アミノ酸、酸性アミノ酸を等モルずつ混合することがより好ましい。 When two or more amino acids are used in combination, metabolic considerations are taken to increase the concentration of fumaric acid and succinic acid in the administered tissue cell mitochondria, and the liquidity of the solution in which the amino acid is dissolved is neutral. It is preferable that the basic amino acid, the neutral amino acid, and the acidic amino acid are mixed in equimolar amounts.
本発明の老化防止剤に含まれるキノン誘導体又はキノンは、下記一般式（I）又は（II）で表されるものが好ましい。 The quinone derivative or quinone contained in the antiaging agent of the present invention is preferably represented by the following general formula (I) or (II).
〔式中、Ａは次式： [In the formula, A represents the following formula:
又は Or
で示される基であり、ｎは１〜９の整数である。〕
一般式（Ｉ）で表される化合物は特公平５−６５３３号公報に開示されているものであり、具体的には、次に挙げる前記公報の実施例１〜１０に記載されたものを含めたものを用いることができる。その他、市販品である、CoQ１０粉末（日清ファルマ社製又は鐘淵化学工業社製）を用いることもできる。
N is an integer of 1-9. ]
The compounds represented by the general formula (I) are those disclosed in Japanese Patent Publication No. 5-6533, and specifically include those described in Examples 1 to 10 of the publication described below. Can be used. In addition, commercially available CoQ 10 powder (manufactured by Nisshin Pharma or Kaneka Chemical Co., Ltd.) can also be used.
（キノン誘導体１）
5−（7−カルボキシ−3−メチル−2,6−オクタジエニル）−2,3,4−トリメトキシ−6−メチルフェノール
（キノン誘導体２）
5−（11−カルボキシ−3,7−ジメチル−2,6,10−ドデカトリエニル）−2,3,4−トリメトキシ−6−メチルフェノール
（キノン誘導体３）
5−（15−カルボキシ−3,7,11−トリメチル−2,6,10,14−ヘキサデカテトラエニル）−2,3,4−トリメトキシ−6−メチルフェノール
（キノン誘導体４）
5−（19−カルボキシ−3,7,11,15−テトラメチル−２,6,10,14,18−エイコサペンタエニル）−2,3,4−トリメトキシ−6−メチルフェノール
（キノン誘導体５）
5−（23−カルボキシ−3,7,11,15,19−ペンタメチル−２,6,10,14,18,22−テトラコサヘキサエニル）−2,3,4−トリメトキシ−6−メチルフェノール
（キノン誘導体６）
6−（7−カルボキシ−3−メチル−2,6−オクタジエニル）−2,3−ジメトキシ−5−メチル−1,4−ベンゾキノン
（キノン誘導体７）
6−（11−カルボキシ−3,7−ジメチル−2,6,10−ドデカトリエニル）−2,3−ジメトキシ−5−メチル−1,4−ベンゾキノン
（キノン誘導体８）
6−（15−カルボキシ−3,7,11−トリメチル−2,6,10,14−ヘキサデカテトラエニル）−2,3−ジメトキシ−5−メチル−1,4−ベンゾキノン
（キノン誘導体９）
6−（19−カルボキシ−3,7,11,15−テトラメチル−２,6,10,14,18−エイコサペンタエニル）−2,3−ジメトキシ−5−メチル−1,4−ベンゾキノン
（キノン誘導体10）
6−（23−カルボキシ−3,7,11,15,19−ペンタメチル−２,6,10,14,18,22−テトラコサヘキサエニル）−2,3−ジメトキシ−5−メチル−1,4−ベンゾキノン
（キノン誘導体11）
（2E,6E,10E,14E,18E,22E,26E,30E,34E,38E）-2-（3,7,11,15,19,23,27,31,35,39-デカメチルテトラコンタ-2,6,10,14,18,22,26,30,34,38-デカエン-1-イル）-5,6-ジメトキシ-3-メチル-1,4-ベンゾキノン
一般式（II）で表される化合物は、人体、微生物等において存在が報告されているものである（Lester,R.L. & Crane,F.L.:J.Biol.Chem．234，2169、1959）。
(Quinone derivative 1)
5- (7-Carboxy-3-methyl-2,6-octadienyl) -2,3,4-trimethoxy-6-methylphenol (quinone derivative 2)
5- (11-carboxy-3,7-dimethyl-2,6,10-dodecatrienyl) -2,3,4-trimethoxy-6-methylphenol (quinone derivative 3)
5- (15-carboxy-3,7,11-trimethyl-2,6,10,14-hexadecatetraenyl) -2,3,4-trimethoxy-6-methylphenol (quinone derivative 4)
5- (19-carboxy-3,7,11,15-tetramethyl-2,6,10,14,18-eicosapentaenyl) -2,3,4-trimethoxy-6-methylphenol (quinone derivative 5 )
5- (23-carboxy-3,7,11,15,19-pentamethyl-2,6,10,14,18,22-tetracosahexaenyl) -2,3,4-trimethoxy-6-methylphenol ( Quinone derivatives 6)
6- (7-Carboxy-3-methyl-2,6-octadienyl) -2,3-dimethoxy-5-methyl-1,4-benzoquinone (quinone derivative 7)
6- (11-carboxy-3,7-dimethyl-2,6,10-dodecatrienyl) -2,3-dimethoxy-5-methyl-1,4-benzoquinone (quinone derivative 8)
6- (15-carboxy-3,7,11-trimethyl-2,6,10,14-hexadecatetraenyl) -2,3-dimethoxy-5-methyl-1,4-benzoquinone (quinone derivative 9)
6- (19-carboxy-3,7,11,15-tetramethyl-2,6,10,14,18-eicosapentaenyl) -2,3-dimethoxy-5-methyl-1,4-benzoquinone ( Quinone derivatives 10)
6- (23-carboxy-3,7,11,15,19-pentamethyl-2,6,10,14,18,22-tetracosahexaenyl) -2,3-dimethoxy-5-methyl-1,4 -Benzoquinone (quinone derivative 11)
(2E, 6E, 10E, 14E, 18E, 22E, 26E, 30E, 34E, 38E) -2- (3,7,11,15,19,23,27,31,35,39-decamethyltetracontour 2,6,10,14,18,22,26,30,34,38-Decaen-1-yl) -5,6-dimethoxy-3-methyl-1,4-benzoquinone represented by general formula (II) These compounds have been reported to exist in the human body, microorganisms, etc. (Lester, RL & Crane, FL: J. Biol. Chem. 234, 2169, 1959).
（キノン；ユビキノン10；コエンザイムQ10）
（2E,6E,10E,14E,18E,22E,26E,30E,34E,38E）-2-（3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-nyl）5,6-dimethoxy-3-methyl-1,4-benzoquinone
薬理学的に許容できる塩としては、塩酸、硫酸等の無機酸の塩、酢酸、フマル酸等の有機酸の塩、ナトリウム、カリウム等のアルカリ金属の塩等を挙げることができる。
(Quinone; Ubiquinone 10; Coenzyme Q10)
(2E, 6E, 10E, 14E, 18E, 22E, 26E, 30E, 34E, 38E) -2- (3,7,11,15,19,23,27,31,35,39-Decamethyltetraconta-2,6 , 10,14,18,22,26,30,34,38-decaen-1-nyl) 5,6-dimethoxy-3-methyl-1,4-benzoquinone
Examples of pharmacologically acceptable salts include salts of inorganic acids such as hydrochloric acid and sulfuric acid, salts of organic acids such as acetic acid and fumaric acid, and salts of alkali metals such as sodium and potassium.
本発明の老化防止剤は、アミノ酸及びこれらの薬理学的に許容できる塩１０〜５００ｍｇと、キノン誘導体若しくはキノン５００〜１０，０００ｍｇを含有することが好ましい。 The anti-aging agent of the present invention preferably contains 10 to 500 mg of an amino acid and a pharmacologically acceptable salt thereof and a quinone derivative or 500 to 10,000 mg of a quinone derivative.
本発明の老化防止剤は、賦形剤、増量剤、清涼剤、甘味剤等の一般的な配合成分を用い、散剤、液剤、錠剤、カプセル剤等の所望の剤型にすることができるが、これらの中でも散剤、液剤が好ましい。 The anti-aging agent of the present invention can be made into desired dosage forms such as powders, liquids, tablets, capsules and the like using general compounding ingredients such as excipients, extenders, refreshing agents, sweeteners and the like. Of these, powders and liquids are preferred.
散剤とするときは、散剤１００ｇ中に、アミノ酸を２５〜８５ｇ含有させ、キノン誘導体又はキノンを１０００〜１５０００ｍｇ含有させる。散剤としたときの１日の有効摂取量は２〜６ｇ程度である。 When it is set as a powder, 25-85g of amino acids are contained in 100g of powder, and 1000-15000mg of quinone derivatives or quinones are contained. When used as a powder, the effective daily intake is about 2 to 6 g.
液剤とするときは、散剤１００ｍｌ中に、アミノ酸を２〜８ｇ含有させ、キノン誘導体又はキノンを１０〜６００ｍｇ含有させる。液剤としたときの１日の有効摂取量は４０〜１００ｍｌ程度である。 When preparing a liquid, 2 to 8 g of amino acid is contained in 100 ml of powder, and 10 to 600 mg of quinone derivative or quinone is contained. When taken as a liquid, the effective daily intake is about 40 to 100 ml.
本発明の老化防止剤は、液体飲料（ドリンク剤）にすることができる。ドリンク剤にする場合には、アミノ酸及びこれらの薬理学的に許容できる塩、並びにキノン誘導体若しくはキノンと共に、通常のドリンク剤に配合する成分を併用することができる。 The anti-aging agent of the present invention can be a liquid beverage (drink agent). In the case of preparing a drink, an amino acid, a pharmacologically acceptable salt thereof, and a quinone derivative or quinone can be used in combination with components to be blended in a normal drink.
本発明の老化防止剤は、食品添加剤（散剤、液剤等の所望の形態にすることができる）にして各種食品や調味料等に添加することができる。例えば、散剤、液剤にして、ふりかけ、粉末スープ、調味料、菓子類、ヨーグルト、マヨネーズ、ドレッシング等に添加することができる。 The anti-aging agent of the present invention can be added to various foods, seasonings and the like as a food additive (can be in a desired form such as a powder or liquid). For example, it can be added as a powder or liquid to sprinkles, powdered soups, seasonings, confectionery, yogurt, mayonnaise, dressing and the like.
実施例１
下記処方の散剤（１日分，分２服用）を調製した。
Example 1
A powder of the following formulation (1 day, 2 doses) was prepared.
５％CoQ１０粉末（日清ファルマ社製） ３００ｍｇ
Ｌ−アルギニン １３００ｍｇ
Ｌ−グルタミン １１００ｍｇ
Ｌ−アスパラギン酸 １０００ｍｇ
この散剤を、記銘力低下を訴え、HDS-R（改訂長谷川式簡易知能評価スケール）法による知能評価スケールで痴呆レベルにある患者に、１日２服（朝食後と夕食後）、約２０週間服用させた。結果を表１に示す。満点は３０点、２０点以下は痴呆、２１点以上は非痴呆を示す。
5% CoQ 10 powder (Nisshin Pharma) 300mg
L-Arginine 1300mg
L-glutamine 1100mg
L-aspartic acid 1000mg
About 20 doses per day (after breakfast and dinner) to patients with dementia level on the intelligence assessment scale by HDS-R (Revised Hasegawa method) I took it for a week. The results are shown in Table 1. A perfect score is 30 points, a score of 20 or less indicates dementia, and a score of 21 or more indicates non-dementia.
＊：視力が回復し、老眼鏡が不要となった。 *: Eyesight recovered and reading glasses were no longer needed.
表１の結果から明らかなとおり、非痴呆レベルへの移行ないし知能評価スケールにおける改善という有意の記憶力改善がみられた。 As is clear from the results in Table 1, there was a significant memory improvement such as a transition to a non-dementia level or an improvement in the intelligence evaluation scale.
この結果から、通称老人ボケと言われる脳血管型及びアルツハイマー型痴呆（いずれも組織呼吸障害に起因する）に有効であると結論できるほか、視力回復効果もみられた。
From this result, it can be concluded that it is effective for cerebrovascular type and Alzheimer type dementia (both caused by tissue respiratory disorder), which is commonly referred to as “senile blurring”, and a visual recovery effect was also observed.
Claims (5)
キノン誘導体が、下記一般式（I）又は（II）：
で表されるものである、請求項１記載の老化防止剤。 The amino acid is one or more selected from aspartic acid, arginine, glutamine, glutamic acid, proline, serine, cysteine,
The quinone derivative has the following general formula (I) or (II):
The anti-aging agent of Claim 1 which is represented by these.
The food additive containing the anti-aging agent in any one of Claims 1-3.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004255288A JP2006069958A (en) | 2004-09-02 | 2004-09-02 | Age resistor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004255288A JP2006069958A (en) | 2004-09-02 | 2004-09-02 | Age resistor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2006069958A true JP2006069958A (en) | 2006-03-16 |
Family
ID=36150943
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004255288A Pending JP2006069958A (en) | 2004-09-02 | 2004-09-02 | Age resistor |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2006069958A (en) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007119588A1 (en) * | 2006-04-10 | 2007-10-25 | Mitsubishi Gas Chemical Company, Inc. | Brain function-improving agent, and functional food containing the improving agent |
| KR100890177B1 (en) * | 2007-08-09 | 2009-03-25 | 광동제약 주식회사 | Composition for the prevention and treatment of diseases related to cognitive dysfunction, containing Hyunsam extract and amino acid combinations as active ingredients |
| JP2011236191A (en) * | 2010-05-11 | 2011-11-24 | Shunzo Kobayashi | Arteriosclerosis improving agent |
| JP2012102054A (en) * | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | In-intestine polyamine fortifier |
| WO2012085954A1 (en) * | 2010-12-21 | 2012-06-28 | D Aniello Antimo | Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease |
| JP2013184956A (en) * | 2012-03-09 | 2013-09-19 | Kyodo Milk Industry Co Ltd | Food for augmenting learning and memorizing capacity |
| WO2013061161A3 (en) * | 2011-10-28 | 2013-11-07 | Anaxomics Biotech Sl | New combination therapies for treating neurological disorders |
| JP2015071604A (en) * | 2014-10-29 | 2015-04-16 | 協同乳業株式会社 | Intestinal polyamine enhancer |
| KR20160057511A (en) * | 2014-11-13 | 2016-05-24 | 대상 주식회사 | Composition for alleviating or inhibiting precocious puberty |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60255749A (en) * | 1984-05-31 | 1985-12-17 | Univ Nagoya | Quinone derivative |
| JPS624227A (en) * | 1985-06-28 | 1987-01-10 | Univ Nagoya | Medicinal drug containing quinone derivative as active component |
| JPH01180823A (en) * | 1988-01-13 | 1989-07-18 | Sawai Seiyaku Kk | Brain disorder treating agent |
| JPH02212421A (en) * | 1989-02-10 | 1990-08-23 | Masaki Imagawa | Remedy for dementia |
| JP2003532679A (en) * | 2000-05-08 | 2003-11-05 | エヌ・ヴイ・ヌートリシア | Nutritional formulation containing ribose and folic acid and its medical use |
| JP2004081010A (en) * | 2002-08-22 | 2004-03-18 | Fancl Corp | Food composition |
| JP2004242509A (en) * | 2003-02-10 | 2004-09-02 | Nisshin Pharma Inc | Foods containing coenzyme Q10 and amino acids |
| JP2005298370A (en) * | 2004-04-07 | 2005-10-27 | Shiseido Co Ltd | Skin preparation for external use for preventing aging of skin |
| JP2005328803A (en) * | 2004-05-21 | 2005-12-02 | Towa Kagaku Kk | Vitality-promoting and aging-preventing food and method for producing the same |
| JP2006045187A (en) * | 2003-12-25 | 2006-02-16 | Bio Igaku Kenkyusho Kk | Therapeutic agent for internal organ failure |
-
2004
- 2004-09-02 JP JP2004255288A patent/JP2006069958A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60255749A (en) * | 1984-05-31 | 1985-12-17 | Univ Nagoya | Quinone derivative |
| JPS624227A (en) * | 1985-06-28 | 1987-01-10 | Univ Nagoya | Medicinal drug containing quinone derivative as active component |
| JPH01180823A (en) * | 1988-01-13 | 1989-07-18 | Sawai Seiyaku Kk | Brain disorder treating agent |
| JPH02212421A (en) * | 1989-02-10 | 1990-08-23 | Masaki Imagawa | Remedy for dementia |
| JP2003532679A (en) * | 2000-05-08 | 2003-11-05 | エヌ・ヴイ・ヌートリシア | Nutritional formulation containing ribose and folic acid and its medical use |
| JP2004081010A (en) * | 2002-08-22 | 2004-03-18 | Fancl Corp | Food composition |
| JP2004242509A (en) * | 2003-02-10 | 2004-09-02 | Nisshin Pharma Inc | Foods containing coenzyme Q10 and amino acids |
| JP2006045187A (en) * | 2003-12-25 | 2006-02-16 | Bio Igaku Kenkyusho Kk | Therapeutic agent for internal organ failure |
| JP2005298370A (en) * | 2004-04-07 | 2005-10-27 | Shiseido Co Ltd | Skin preparation for external use for preventing aging of skin |
| JP2005328803A (en) * | 2004-05-21 | 2005-12-02 | Towa Kagaku Kk | Vitality-promoting and aging-preventing food and method for producing the same |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007119588A1 (en) * | 2006-04-10 | 2007-10-25 | Mitsubishi Gas Chemical Company, Inc. | Brain function-improving agent, and functional food containing the improving agent |
| JPWO2007119588A1 (en) * | 2006-04-10 | 2009-08-27 | 三菱瓦斯化学株式会社 | Brain function improving agent and functional food containing the improving agent |
| KR100890177B1 (en) * | 2007-08-09 | 2009-03-25 | 광동제약 주식회사 | Composition for the prevention and treatment of diseases related to cognitive dysfunction, containing Hyunsam extract and amino acid combinations as active ingredients |
| JP2011236191A (en) * | 2010-05-11 | 2011-11-24 | Shunzo Kobayashi | Arteriosclerosis improving agent |
| JP2012102054A (en) * | 2010-11-11 | 2012-05-31 | Kyodo Milk Industry Co Ltd | In-intestine polyamine fortifier |
| WO2012085954A1 (en) * | 2010-12-21 | 2012-06-28 | D Aniello Antimo | Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease |
| WO2013061161A3 (en) * | 2011-10-28 | 2013-11-07 | Anaxomics Biotech Sl | New combination therapies for treating neurological disorders |
| JP2013184956A (en) * | 2012-03-09 | 2013-09-19 | Kyodo Milk Industry Co Ltd | Food for augmenting learning and memorizing capacity |
| JP2015071604A (en) * | 2014-10-29 | 2015-04-16 | 協同乳業株式会社 | Intestinal polyamine enhancer |
| KR20160057511A (en) * | 2014-11-13 | 2016-05-24 | 대상 주식회사 | Composition for alleviating or inhibiting precocious puberty |
| KR101683007B1 (en) | 2014-11-13 | 2016-12-07 | 대상 주식회사 | Composition for alleviating or inhibiting precocious puberty |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6591995B2 (en) | Dopa decarboxylase inhibitor composition | |
| BR112018008710B1 (en) | high intensity sweeteners | |
| ES2692723T3 (en) | Metabolism enhancing agent, which comprises a rare fatty acid | |
| JP5783165B2 (en) | Method for producing reduced pyrroloquinoline quinone | |
| CN101578284B (en) | Agent for improving insulin resistance | |
| JP2006069958A (en) | Age resistor | |
| TWI309162B (en) | Amino acid composition for improving functional disorder of liver | |
| US9062086B2 (en) | N-acetyl L-cysteine chelates and methods for making and using the same | |
| JP5128828B2 (en) | Anti-inflammatory and antioxidant | |
| US20120213757A1 (en) | Nutritional supplement composition | |
| EP4226919A1 (en) | Ferroptosis inhibitor | |
| WO2010072209A3 (en) | Food supplements based on pantothenic acid | |
| EP4122536A1 (en) | Coenzyme q production promoter and coenzyme q production promoting method | |
| JP2011256166A (en) | Stable aqueous preparation | |
| JP2006151909A (en) | Composition for internal use | |
| JP2013192515A (en) | Oyster extract | |
| JP6873904B2 (en) | Xanthine oxidase inhibitor | |
| JP6191616B2 (en) | Oral solution | |
| JP5384697B2 (en) | Anti-inflammatory and antioxidant | |
| JP6431635B1 (en) | Beverage and method for producing the same | |
| JP2018002639A (en) | Acidic composition containing folic acid with excellent stability | |
| JP2018020963A (en) | Alcohol metabolism promoting agent and alcohol disorder prevention food and drink | |
| CN107106540A (en) | The fat prevention as active ingredient or therapeutic composition comprising alpha lipoic acid and N acetylcysteines | |
| JPWO2007049628A1 (en) | Blood fluidity improver | |
| JP4147280B2 (en) | Glutamine-containing energy-added amino acid composition or amino acid solution |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060517 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100105 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100518 |